A recent study illustrated that serum CENPF antibody could predict clinical response to infliximab in rheumatoid arthritis patients (22), and it further demonstrated potential diagnostic value for early stage HCC and colorectal cancer (23, 24). The gene discussed is CENPF; the disease is hepatocellular carcinoma.